Despite major advances in prevention and treatment, febrile neutropenia (absolute neutrophil count <0.5×10(9)/L) remains one of the most concerning complications of cancer chemotherapy, especially in patients receiving myelosuppressive chemotherapy [1]. Outside the context of Oncology, few data are currently available for febrile neutropenia, especially for febrile neutropenia related to non-chemotherapy drugs, called “idiosyncratic agranulocytosis”.
